ALLOCATION OF R+D+i RESOURCES
Grifols boosted its net R+D+i investments in 2019
Grifols’ allocations to R+D+i increased by 12.9% to EUR 329 million, which EQUAL TO 6.5% of REVENUES
TOTAL INVESTMENT in R+D+i

Human resources
Research centers

GRIFOLS’ INNOVATION ECOSYSTEM GENERATES OPPORTUNITIES AND COLLABORATIONS

Grifols’ innovation ecosystem generates opportunities that promote the ongoing exploration of areas of medicine, complementary treatments for specific diseases AND promote research to treat more common diseases

GRIFOLS’ INNOVATION ECOSYSTEM
AN OPEN INNOVATION ECOSYSTEM THAT PROMOTES KNOWLEDGE AND TALENT BEYOND THE LIMITS OF THE COMPANY
INVESTEES

AlbaJuna Therapeutics – Spain: Development of a new treatment strategy based on antibodies with a high potential to neutralize HIV and viral reservoirs at the cellular level

Alkahest – United States: Research on the benefits of plasma proteins to treat age-related cognitive impairment

Araclon – Spain: Specialized in diagnostic tests and the development and research of new treatments for Alzheimer’s

GigaGen – United States: Research and development of new recombinant immunoglobulins using immune-system cells from donors 

VCN Biosciences – Spain: Research and development of oncolytic viruses to treat solid tumors